Skeletal muscle is recognized as vital to physical movement, posture, and breathing. In a less known but critically important role, muscle influences energy and protein metabolism throughout the body. Muscle is a primary site for glucose uptake and storage, and it is also a reservoir of amino acids stored as protein. Amino acids are released when supplies are needed elsewhere in the body. These conditions occur with acute and chronic diseases, which decrease dietary intake while increasing metabolic needs. Such metabolic shifts lead to the muscle loss associated with sarcopenia and cachexia, resulting in a variety of adverse health and economic consequences. With loss of skeletal muscle, protein and energy availability is lowered throughout the body. Muscle loss is associated with delayed recovery from illness, slowed wound healing, reduced resting metabolic rate, physical disability, poorer quality of life, and higher health care costs. These adverse effects can be combated with exercise and nutrition. Studies suggest dietary protein and leucine or its metabolite \( \beta \)-hydroxy-\( \beta \)-methylbutyrate (HMB) can improve muscle function, in turn improving functional performance. Considerable evidence shows that use of high-protein oral nutritional supplements (ONS) can help maintain and rebuild muscle mass and strength.

This review of muscle metabolism describes how amino acids stored as protein in muscle can be broken down through proteolysis for ultimate use in energy production. Such breakdown occurs when energy demands are high (as with stress-induced hypermetabolism), or when supplies are low (as in severe starvation or longer-term protein energy malnutrition). Both of these states can be hallmarks of many diseases, either directly as a result of disease-related dysregulation of metabolism (such as in the extreme case of cancer cachexia) or, more subtly, as a result of the general illness-associated loss of appetite. Muscle is therefore crucially important during illness, both for its role in balancing the metabolic needs of other organs and for its reserves of protein for use in energy production. Yet, during illness, the maintenance of muscle mass through exercise and nutrition are often overlooked or difficult to address, and muscle atrophy develops. Even more subtle is aging-related muscle loss, which can dramatically increase morbidity and mortality of otherwise survivable illnesses in the aged. This review also illustrates the consequences of muscle atrophy in aging and illness and proposes steps to combat these challenges.
**Muscle Basics**

*Muscle Structure and Classification*

Skeletal muscle comprises the fibrillar proteins myosin (a thick filament) and actin (a thin filament) that interact to cause muscle contraction, a process requiring energy in the form of adenosine triphosphate (ATP). Different muscle types have been classified according to histochemical features, structural protein composition, and major metabolic properties. Most commonly, skeletal muscles are referred to as either “slow” or “fast” to reflect speeds of contraction, or the shortening of myosin heavy chain (MHC) protein. The velocity of this shortening is dependent on the MHC isoform present; “fast” fiber isoforms MHCIa and IIb demonstrate a higher shortening velocity than their “slow” fiber MHCI counterparts. Classic histochemical staining methods also classify muscle as type I (slow) and type II (fast) based on the myosin ATPase enzyme forms revealed. Recently, these types have been further distinguished based on histology (types I, IC, IIAC, IIA, IIAB, and IIB).

**Muscle Metabolism and Interorgan Crosstalk**

Glucose regulation is central to energy balance both within muscle fibers and throughout the body. In the cytoplasm of most cells, glucose undergoes glycolysis to produce the substrate for ATP generation. Muscle fibers are also characterized on the basis of the speed and manner in which they metabolize glucose. The terms “fast” and “slow” can indicate the type of glucose metabolism occurring within the fiber. Slow muscles, which use aerobic metabolism, contain a high density of capillaries and oxidative enzymes that allow a greater resistance to fatigue. Fast muscles, which depend on anaerobic metabolism, or glycolysis, can quickly generate ATP and therefore contract more readily. Fast muscles also fatigue sooner than slow fibers, as the conversion of glucose to pyruvate generates less ATP than can be generated by using the rest of central metabolism, ultimately generating CO₂.

Muscle has the ability to store glucose in the form of glycogen, which facilitates the rapid initiation of energy production for contraction even when glucose is not readily available from the diet. This unique capacity, shared also by the liver and kidneys, makes skeletal muscle an important metabolic organ that helps all organs have access to essential energy substrates during fasting. Furthermore, the amino acids stored in muscle as protein can be broken down as a last resort during times of starvation or extreme energy shortfalls. Patterns of glucose utilization throughout the body as a whole reflect feeding status (Figure 1; Table 1). Based on a classic study of the fed state (measurement within 3 hours of eating), researchers estimated that 25% to 35% of an ingested carbohydrate load was quickly extracted from circulation and stored by the liver. Of the remaining glucose, approximately 40% was disposed in the muscle and 10% in the kidney. The brain used 15% to 20% of post-meal glucose.

In the fasted state (after 14 to 16 h without eating), the liver provides approximately 80% of glucose that is released into circulation. About half of this glucose comes from the breakdown of stored glycogen, and the rest from the metabolism of sources other than carbohydrate or glycogen, including certain amino acids, through a process known as gluconeogenesis. Interactions between muscle and liver are largely responsible for regulating carbohydrate metabolism and for achieving energy balance in normal fed and fasted states; the kidneys play a role similar to that of the liver, but to a lesser extent. In addition, muscle tissue stores amino acids as protein, and adipose tissue serves as a depot of glycerol and fatty acids. As needed, amino acids and fatty acids can be metabolized to form acetyl coenzyme A for the tricarboxylic acid (TCA) cycle.

As glycogen stores become depleted, increasingly more glucose is produced by gluconeogenesis. Gluconeogenesis provides 70% of glucose released into the body 24 hours after eating, and 90% by 48 hours. As fasting is prolonged, the kidneys contribute increasingly higher amounts of glucose from gluconeogenesis.

Ultimately, amino acids stored in skeletal muscle are metabolized when the need for gluconeogenesis substrate is greatest. Skeletal muscle houses nearly 75% of all protein in the body and constitutes an important contributor to gluconeogenesis in states of drastic depletion. Maintenance of muscle protein content depends on the balance between protein synthesis and degradation. Under normal conditions, muscle protein mass gains during the fed state balance losses during the fasted state. However, under severe metabolic stress generated by serious illness or injury, muscle protein can become...
Mechanisms of Muscle Growth and Strength Increase

Muscle adapts positively to demands placed on it, such as the increased contractile activity associated with endurance training or the increased loading attributable to strength training. This tremendous plasticity is evident as muscle tissue accretion, specific changes within muscle, and muscle tissue breakdown. Muscle growth, or hypertrophy, occurs when protein synthesis within the muscles outpaces protein degradation. This process can be positively regulated by mammalian target of rapamycin (mTOR) signaling induced by insulin after calorie ingestion, by hormones such as testosterone, and by exercise. 

Mechanisms of Muscle Loss in Aging, Inactivity, Sickness, and Frailty

This ability of skeletal muscle to change dynamically in response to body conditions is also manifest as changes resulting from injury, illness, or aging. When the metabolic demands placed on muscle outweigh the protein synthesis that occurs from dietary intake and after exercise, muscle mass is lost, metabolic storage products are depleted, and muscle fiber balance changes.

Aging may lead to a loss of muscle mass resulting from both the shrinking of muscle fibers (atrophy) and the elimination of fibers altogether (Figure 2). This condition is known as primary sarcopenia, the age-related loss of muscle mass and function. Although both fiber types I and II lose mass, aging causes preferential atrophy of type II fibers; the net change is thus from type II to type I fibers, or from fast to slow muscle fibers. Because fast muscle fibers mobilize ATP and create tension more readily than slow fibers, this shift can leave older adults without the energy to perform daily tasks. This shift to type I 

Muscle Plasticity: Changes in Muscle Mass, Strength, and Function

Skeletal muscle is remarkably plastic. It changes continuously in response to calorie and nutrient intake, illness, and physical stress. Changes in adult skeletal muscle also may occur as fiber-type switching, which is influenced by changes in physical activity, loading, nerve stimulation, or hormone and cytokine levels. 

Mechanisms of Muscle Metabolism in Fasted and Fed States

| Table 1 |
|------------------|------------------|
| **Fed State**     | **Fasted State**  |
| Diet-sourced glucose (exogenous glucose) is absorbed from the intestine to circulate in blood; glucose serves as an energy source in cells throughout the body. Cytoplasmic glucose undergoes glycolysis, in turn producing ATP. Glucose is primarily taken up by muscle and liver, where it can be used for energy or stored as glycogen (Glycogen synthesis). Gluconeogenic substrates are stored in various organs (eg, pyruvate in liver, glyceral in fat, and amino acids in muscle). | Little or no blood glucose from dietary sources; alternative energy sources are needed for function of tissues body-wide. Glycogen stored in liver, kidney, and muscle is broken down to provide glucose as energy source (Glycogenolysis). Muscle uses glycogen-sourced glucose internally; liver and kidney can supply glucose to circulation. Endogenous generation of glucose from noncarbohydrate carbon substrates, such as pyruvate, lactate, glycerol, and glucogenic amino acids (Gluconeogenesis); occurs primarily in the liver and muscle, and to a lesser extent in the kidney. |
slow fibers leads to a corresponding increase in their characteristic oxidative metabolism relative to the glycolytic metabolism that occurs in type II fast fibers. Exacerbating the problems caused by muscle degradation in aging, it is possible that type I oxidative fibers normally experience higher protein turnover (i.e., protein synthesis and degradation), are less able to grow in size, and have different responses to insufficient nutrient intake, although these fiber-type differences remain poorly understood.17,18

Beyond aging, muscle wasting is associated with many pathological states and chronic diseases, such as malnutrition, cancer, chronic kidney disease, chronic obstructive pulmonary disease, burns, muscular dystrophies, acquired immunodeficiency syndrome, sepsis, and immune disorders, and forced immobilization and bed rest are devastating to patients who are already challenged by these factors (Figure 2).14,17 Most of these pathological conditions are associated with variable degrees of local and/or systemic chronic inflammation, which plays a crucial role in the onset of muscle atrophy. Loss of muscle mass is frequently associated with the presence of sarcopenia in this population is a clinical syndrome called frailty. The most accepted physiological framework for understanding vulnerabilities resulting from illness stress has subsided. Thus, when the dietary proteins supplied are inadequate to meet needs, muscle protein is broken down to supply amino acids throughout the body. This reaction renews waste nitrogen, which requires further energy to convert to urea, thereby exacerbating the problem of the energy shortfall.24

### Complications Associated With Loss of Muscle

As aging and illness lead to muscle breakdown and atrophy, reduced muscle mass leaves patients without a crucial reservoir of amino acids and effector molecules, such as cytokines, released by muscle, to help the body combat illness, infection, and wasting (Figure 3).23,25–27 Therefore, muscle atrophy is associated with a wide range of harmful health effects that can be life changing, especially for older people.28–36 The most relevant condition associated with the presence of sarcopenia in this population is a clinical syndrome called frailty. The most accepted physiological framework explaining frailty and its consequences was proposed by Walston and Fried,37 who described a relationship between sarcopenia and energy imbalance called the “frailty cycle.” This cycle affects multiple systems, especially those susceptible to changes in hormones (mainly sexual hormones, IGF-1, and insulin) and the progressive development of a proinflammatory state.38–40 Additional biomarkers have recently been identified for roles in frailty, such as those related to endothelial dysfunction or micro RNAs central to the aging process.41,42 Frailty can be defined as an age-associated biological syndrome characterized by a decreased biological reserve resulting from a decline in multiple physiological systems that leaves the individual at risk for developing poor outcomes (disability, death, and hospitalization) in the presence of stressors.53,44 The prevalence of frailty in people older than 65 is approximately 10%, increases with age, and is greater in women.45

Frailty is now a recognized clinical medical syndrome that provides a biological framework for understanding vulnerabilities resulting from aging or chronic conditions.44,46 It is clinically important to detect frailty in those at risk of developing disability. As aging progresses, frailty increases as the prognostic factor for death and incident disability.7,47 Frailty and its underlying sarcopenia have been shown to predict risk of death, disability, and other adverse outcomes, including muscle mass atrophy, metabolic deterioration, slowed

### Table 2

<table>
<thead>
<tr>
<th>Effector</th>
<th>Mediator</th>
<th>Major Pathway(s)</th>
<th>Consequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mammalian target of rapamycin (mTOR)</td>
<td>+ Induced by BCAAs, HMB</td>
<td>Interacts with protein translation machinery to facilitate initiation and elongation</td>
<td>mTOR stimulation by a number of pathways increases protein synthesis</td>
</tr>
<tr>
<td>Insulinlike growth factor (IGF1)</td>
<td>+ Stimulated by meal-induced insulin + Stimulated by exercise</td>
<td>IGF1R → PI3K → AKT → mTOR</td>
<td>Reduced IGF1 from decreased eating and/or exercise leads to reduced protein synthesis and to muscle wasting</td>
</tr>
<tr>
<td>Myostatin/Activin</td>
<td>+ Produced by skeletal muscle</td>
<td>Activin receptors (ACTRIIA/B) → Smad2/3 → mTOR</td>
<td>Myostatins negatively regulate protein synthesis</td>
</tr>
<tr>
<td>Inflammatory cytokines (TNFα, IL-1)</td>
<td>+ Upregulated by illness, injury</td>
<td>Cytokine receptors → NFκB, p38, JAK, Caspases, E3 ligases</td>
<td>Inflammation leads to apoptosis or autophagy-mediated muscle cell loss</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>+ Levels are increased by diet and sunlight</td>
<td>Vitamin D receptor → gene expression or repression in myogenic cells</td>
<td>Vitamin D positively influences muscle growth</td>
</tr>
</tbody>
</table>

AKT, protein kinase B; BCAA, branched-chain amino acid; FoxO, forkhead box protein O; HMB, β-Hydroxy-β-Methylbutyrate; IGF1R, insulinlike growth factor 1 receptor; JAK, janus kinase; MURF1, muscle RING-finger protein-1 p38, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; UPS, ubiquitin-proteasome system.
have not yet assessed in the clinical setting. Nonetheless, specific cachexia. Sarcopenia can be diagnosed when a patient has muscle mass that is at least 2 SDs below the relevant population mean and also presents with a low gait (walking) speed. In addition, low muscle strength and general physical performance may be taken into consideration. Cachexia can be diagnosed when at least 5% of body weight is lost within 12 months in the presence of underlying illness, and 3 of the following criteria are also met: decreased muscle strength, increased fatigue, anorexia, low fat-free mass index, abnormal biochemistry, increased inflammatory markers C-reactive protein (≥5.0 mg/L) or IL-6 (≥4.0 pg/mL), anemia (<12 g/dL), or low serum albumin (<3.2 g/dL).

Recent research into the molecular adaptations associated with the development of or that result from muscle atrophy and metabolic depletion may lead to the identification of biomarkers and, therefore, improvements in early detection (Table 2). A variety of signaling pathways known to positively influence muscle growth (bone morphogenetic proteins, brain-derived neurotrophic factors, follistatin, and irisin), as well as those known to negatively regulate muscle growth (transforming growth factor β, myostatin, activins, and growth and differentiation factor-15) and factors associated with muscle function and dysfunction (C-terminal agrin fragment and skeletal muscle specific troponin T) may emerge as biomarkers for muscle atrophy in aging and disease. To date, there is no universally recognized biomarker for muscle atrophy, but recent research in the field suggests that the combination of several biomarkers may facilitate the adequate diagnosis of muscle atrophy. Identification of such biomarkers and their incorporation into validated testing instruments should allow early identification of muscle atrophy (improving prognosis, and likely reducing cost to health care systems), but may also provide exciting targets for the development of new medications.

**Nutritional Strategies for Maintaining and Rebuilding Muscle**

Treatment of patients at risk can prevent or delay onset of muscle atrophy, or even target rebuilding of muscle when muscle atrophy is already evident (Figure 4). As a first step, treatment must provide adequate energy so that muscle proteins and their constituent amino acids are spared as an energy source. In addition, high protein intake is vital to treatment of muscle atrophy or for delaying its onset. To note, it should be noted that the range of protein needs can vary widely from patient to patient. Because muscle mass may decrease or remain the same (based largely on how much protein synthesis outpaces protein degradation), the most direct way to prevent muscle loss is to ensure.

**Detection and Treatment of Muscle Loss**

**Who is at Risk of Muscle Atrophy, and How Do We Identify It?**

Screening is crucial for predicting risk, and proper, timely intervention can reduce or eliminate the ensuing muscle mass and metabolic atrophy, substantially affecting morbidity, mortality, and cost. Special attention should be paid to the main risk categories: people who are malnourished or at risk of malnutrition for any reason; frail adults, especially the very old; people who become deconditioned and lose muscle due to age- and disability-related physical inactivity; those with diseases or conditions with inflammatory components, such as chronic heart failure, chronic or acute kidney disease, cancer, severe infection and sepsis, insulin resistance/diabetes, intensive care unit–acquired weakness, and wound/surgical recovery. Reaching an accurate diagnosis of age- or disease-related muscle atrophy is difficult, and a number of criteria have been proposed but have not yet assessed in the clinical setting. Nonetheless, specific criteria and measures can be used to diagnose sarcopenia or cachexia. Sarcopenia can be diagnosed when a patient has muscle mass that is at least 2 SDs below the relevant population mean and also presents with a low gait (walking) speed. In addition, low muscle strength and general physical performance may be taken into consideration. Cachexia can be diagnosed when at least 5% of body weight is lost within 12 months in the presence of underlying illness, and 3 of the following criteria are also met: decreased muscle strength, increased fatigue, anorexia, low fat-free mass index, abnormal biochemistry, increased inflammatory markers C-reactive protein (≥5.0 mg/L) or IL-6 (≥4.0 pg/mL), anemia (<12 g/dL), or low serum albumin (<3.2 g/dL).

Recent research into the molecular adaptations associated with the development of or that result from muscle atrophy and metabolic depletion may lead to the identification of biomarkers and, therefore, improvements in early detection (Table 2). A variety of signaling pathways known to positively influence muscle growth (bone morphogenetic proteins, brain-derived neurotrophic factors, follistatin, and irisin), as well as those known to negatively regulate muscle growth (transforming growth factor β, myostatin, activins, and growth and differentiation factor-15) and factors associated with muscle function and dysfunction (C-terminal agrin fragment and skeletal muscle specific troponin T) may emerge as biomarkers for muscle atrophy in aging and disease. To date, there is no universally recognized biomarker for muscle atrophy, but recent research in the field suggests that the combination of several biomarkers may facilitate the adequate diagnosis of muscle atrophy. Identification of such biomarkers and their incorporation into validated testing instruments should allow early identification of muscle atrophy (improving prognosis, and likely reducing cost to health care systems), but may also provide exciting targets for the development of new medications.

**Nutritional Strategies for Maintaining and Rebuilding Muscle**

Treatment of patients at risk can prevent or delay onset of muscle atrophy, or even target rebuilding of muscle when muscle atrophy is already evident (Figure 4). As a first step, treatment must provide adequate energy so that muscle proteins and their constituent amino acids are spared as an energy source. In addition, high protein intake is vital to treatment of muscle atrophy or for delaying its onset. To note, it should be noted that the range of protein needs can vary widely from patient to patient. Because muscle mass may decrease or remain the same (based largely on how much protein synthesis outpaces protein degradation), the most direct way to prevent muscle loss is to ensure.

**Fig. 3.** Complications of lean body mass (muscle) loss.

**Fig. 4.** Treatments for sarcopenia. It is currently recommended that patients at risk of or suffering from sarcopenia consume a diet high in protein, engage in resistance exercise, and take supplements of the leucine metabolite HMB.
that sufficient protein is ingested. Use of high-protein oral nutritional supplements (ONS; ≥20% of total calories as protein) may be beneficial to such patients.10

By definition, the essential amino acids (EAAs) play a central role in protein nutritional status. Some amino acids play roles that are distinct from the traditional one of protein building blocks; many of these have little or nothing to do with protein synthesis, and are thus not included here. However, of central importance to the current discussion are the branched-chain amino acids (BCAAs), especially leucine.65,71,72 BCAAs promote protein synthesis in the muscles through a number of pathways.65 In particular, they are now known to have a key role in altering tissue response to a meal, the post-prandial response, especially in muscle, where they signal a reduction in protein breakdown and an increase in protein synthesis, resulting in net accretion of protein in muscle and helping to regulate blood amino acid levels. However, aspects of this postprandial regulation are not as robust in aged muscle, and muscle in hypercatabolic conditions, such as cancer, is challenged and its normal system is overwhelmed. In these cases, a substantial body of research suggests that significantly more of these amino acids are required in the diet to overcome resistance to protein anabolism; very high doses, such as 10 to 15 g of BCAAs, or 3 g or more of leucine per meal, have been studied to combat muscle loss in the elderly,44 although this may be a result of improved protein synthesis that does not lead to muscle mass accretion.73–75

This resistance to the normal of BCAAs in muscle protein homeostasis has prompted studies into leucine’s mechanism of action. These have identified the leucine metabolite β-hydroxy β-methylbutyrate (HMB) as a potent stimulator of protein synthesis as well as an inhibitor of protein breakdown in the extreme case of cachexia.55,72,76–84 A growing body of evidence suggests HMB may help slow, or even reverse, the muscle loss experienced in sarcopenia and improve measures of muscle strength.43,65,72,76–84 However, dietary leucine does not provide a large amount of HMB; only a small portion, as little as 5%, of catabolized leucine is metabolized into HMB.85 Thus, although dietary leucine itself can lead to a modest stimulation of protein synthesis by producing a small amount of HMB, direct ingestion of HMB more potently affects such signaling, resulting in demonstrable muscle mass accretion.71,80 Indeed, a vast number of studies have found that supplementation of HMB to the diet may reverse some of the muscle loss seen in sarcopenia and in hypercatabolic disease.65,72,83,86,87 The overall treatment of muscle atrophy should include dietary supplementation with HMB, although the optimal dosage for each condition is still under investigation.58

In addition to dietary protein, EAAs/BCAAs including leucine, the leucine metabolite HMB, a number of other dietary or supplemental components have been explored for their ability to positively influence muscle mass during sarcopenia. These include creatine monohydrate, a variety of antioxidants, ornithine γ-ketoglutarate, omega-3 fatty acids, ursoic acid, and nitrates.68,88–90 Given the length of this list, its growing nature, and the difficulty many aged individuals experience ingesting proper calories and nutrients, additional studies will be needed to determine which components are most beneficial to maintaining muscle mass, as well as their optimal doses and administration routes both in isolation and in combination.

Physical Activity Is Also Key

Nutrition is important and can counteract metabolic alterations induced during periods of significant stress and inflammation; however, sufficient exogenous provisions of protein and energy substrates alone cannot completely eliminate or reverse the deteriorations associated with aging or the deleterious impact inadequate control and regulation of inflammation have on muscle.23,60,69 Protein synthesis occurs in muscle fibers following their contraction,73 and physical activity has been shown to induce a number of anabolic signaling pathways.52 Physical activity can likewise reduce degradation of muscle protein.53,54 Even more, a lack of physical activity increases the resistance of muscle to anabolism, particularly the synthesis of proteins from amino acids.55 An exercise component to muscle atrophy treatment is therefore highly recommended, and exercise also may prevent the onset of sarcopenia later in life, possibly by increasing the presence of type I fibers that are less susceptible to degradation during sarcopenia.72,75,66,69 Although aerobic and other types of exercise are all preferable to a lack of physical activity, resistance exercise in particular has been shown repeatedly to improve rates of protein synthesis and reverse muscle mass loss.68,80,93 This may be attributable to differential effects on muscle fiber types.8 It is therefore recommended that patients with muscle atrophy or at risk of developing muscle atrophy engage a regular exercise program containing both aerobic and anaerobic components, and the importance of appropriate resistance training cannot be overstated. Although this must be tailored to the individual’s current physical status, it should also periodically be reviewed and increased to maximize its impact.

Although resistance exercise and general physical activity are important to the stimulation of protein synthesis from amino acids in the diet, some aged and ill individuals experiencing extensive muscle atrophy are likely to have difficulty engaging in physical activities because of low energy and other medical complications. Nutrition and some supplements can be used to bolster results of exercise, both preventively and during sarcopenia. For example, bioactive substances known as nutraceuticals that mimic the molecular effects of exercise can induce signaling pathways that are thought to support or even underlie exercise’s effects on health and muscle mass accretion. Found in a variety of foods, including some common fruits, green tea, and even red wine, these compounds can be isolated and added to nutritional supplements used in the treatment of muscle atrophy.44

Summary and Conclusions

The classic physical functions of skeletal muscle are well known, but skeletal muscle is increasingly recognized as one of the key regulators of energy and protein metabolism by way of metabolic crosstalk between body organs. Skeletal muscle is the primary site for glucose uptake and storage, and it is likewise a reservoir of amino acids that sustain protein synthesis in all other body sites. When dietary glucose intake decreases or metabolic needs increase, stored glucose is mobilized from liver, while energy is released from fat deposits. When these energy supplies are depleted, the muscle reservoir of amino acids stores is tapped, and muscle proteins are broken down to provide amino acids for gluconeogenesis, thereby supplying energy to other parts of the body.

Undernutrition and resultant muscle loss (muscle atrophy), as associated with aging and disease, can lead to adverse health and economic consequences. Conditions and diseases that lower dietary intake and increase nutrient needs are associated with catabolism of skeletal muscle, which in turn limits availability of protein and energy throughout the body. Loss of muscle mass, strength, and function has adverse consequences: slowed wound healing and recovery from illness, physical disability (due both to overall reduction of muscle status), as well as selective losses in type I fibers, which are essential for balance recovery (and thus fall prevention), poorer quality of life, and higher health care costs.

Nutrition and exercise are key to growth and maintenance of muscle promoting overall health, well-being, and recovery from disease. A wealth of research underscores the importance of a few key dietary components: protein (EAAs/BCAAs in particular), and the leucine metabolite HMB. Others will very likely be added to this list as our knowledge base grows. In addition, physical activity, especially
resistance strength training, is essential to the treatment of muscle atrophy. Others will very likely be added to this list as our knowledge base grows. Considerable evidence shows that ONS and enteral feeding formulations can help maintain and rebuild muscle mass and strength. Further studies are needed to show support for functional outcomes, such as ability to perform activities of daily living and maintain or restore independence.

Acknowledgments

The authors thank Jeffrey H. Baxter and Abby Sauer from ANR&D for their critical review of this article, as well as Cecilia Hofmann, PhD, and Hilary North Scheler, PhD (C Hofmann & Associates, Western Springs, IL), for valuable assistance with efficient compilation of the medical literature and with editing this English-language review article.

References


